These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
3. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D D2EFT Study Group Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744 [TBL] [Abstract][Full Text] [Related]
4. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F; J Antimicrob Chemother; 2016 Apr; 71(4):1056-62. PubMed ID: 26702926 [TBL] [Abstract][Full Text] [Related]
5. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562 [TBL] [Abstract][Full Text] [Related]
6. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148 [TBL] [Abstract][Full Text] [Related]
8. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance. Abdullahi A; Diaz AG; Fopoussi OM; Beloukas A; Fokom Defo V; Kouanfack C; Torimiro J; Geretti AM J Antimicrob Chemother; 2024 Feb; 79(2):339-348. PubMed ID: 38153241 [TBL] [Abstract][Full Text] [Related]
9. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC; Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787 [TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640 [TBL] [Abstract][Full Text] [Related]
11. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S; J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905 [TBL] [Abstract][Full Text] [Related]
12. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
13. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546 [TBL] [Abstract][Full Text] [Related]
14. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926 [TBL] [Abstract][Full Text] [Related]
15. Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. Villabona-Arenas CJ; Eymard-Duvernay S; Aghokeng A; Guichet E; Toure-Kane C; Bado G; Koulla-Shiro S; Delaporte E; Ciaffi L; Peeters M AIDS Res Hum Retroviruses; 2018 Jun; 34(6):477-480. PubMed ID: 29575909 [TBL] [Abstract][Full Text] [Related]
16. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS; PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032 [TBL] [Abstract][Full Text] [Related]
17. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A; Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050 [TBL] [Abstract][Full Text] [Related]
18. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors. Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A; Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]